AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35128939 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details not available
Number of subjects: 0
Study 35129007 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35129069 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamitrinib, a mitochondria-targeted small molecule Hsp90 inhibitor
Number of subjects: 0
Study 35129069 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35129146 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD assessment with real time quantitative polymerase chain reaction (qPCR) in 283 patients
Number of subjects: 1388
Study 35129146 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD assessment with multiparametric flow cytometry (MFC)-MRD in 107 patients
Number of subjects: 1388
Study 35129146 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR-MRD ≥10-3 on day 78
Number of subjects: 1388
Study 35129211 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular treatment
Number of subjects: 68
Study 35129211 — intervention group
Group type: COMPARATOR
Intervention: Patching treatment
Number of subjects: 68
Study 35129211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 68
Study 35129214 — intervention group
Group type: COMPARATOR
Intervention: Valproic acid
Number of subjects: 856
Study 35129214 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (3-day treatment)
Number of subjects: 856
Study 35129282 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide-induced liver injury in Indian patients (n=16)
Number of subjects: 17
Study 35129282 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide-induced liver injury in US patients (n=1)
Number of subjects: 17
Study 35129282 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Indian cohort vs US DILIN patients
Number of subjects: 17
Study 35129301 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to partners (diagnosed prior to current pregnancy)
Number of subjects: 1392
Study 35129301 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to partners (diagnosed during current pregnancy)
Number of subjects: 1392
Study 35129317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after 3-month dual antiplatelet therapy (DAPT)
Number of subjects: 2980
Study 35129317 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor-based 12-month DAPT
Number of subjects: 2980
Study 35129374 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily oral cabotegravir 30 mg for 4 weeks
Number of subjects: 47
Study 35129374 — intervention group
Group type: EXPERIMENTAL
Intervention: Five 600-mg (3-mL) intramuscular cabotegravir LA injections at weeks 5, 9, 17, 25, and 33
Number of subjects: 47
Study 35129374 — intervention group
Group type: COMPARATOR
Intervention: Daily oral standard-of-care
Number of subjects: 47
Study 35129407 — intervention group
Group type: EXPERIMENTAL
Intervention: VenoValve implantation
Number of subjects: 11
Study 35129457 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling intervention starting in late pregnancy up to 1 year after delivery.
Number of subjects: 1056
Study 35129457 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 1056
Study 35129457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer counseling)
Number of subjects: 1056
Study 35129466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Surveillance (IS) - defined as annual computed tomography for 3 years postoperatively
Number of subjects: 4682
Study 35129466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Surveillance (IS)
Number of subjects: 4682
Study 35129472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathoracic implantation of multidrug-eluting microdevices (IMDs) containing 12 chemotherapeutic agents, inserted intraoperatively and retrieved with the resected specimen.
Number of subjects: 5
Study 35129514 — intervention group
Group type: EXPERIMENTAL
Intervention: ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy)
Number of subjects: 0
Study 35129514 — intervention group
Group type: COMPARATOR
Intervention: TSH (Two-stage hepatectomy)
Number of subjects: 0
Study 35129526 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using Dexcom G6
Number of subjects: 70
Study 35129803 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab infusion after first-line immunotherapy
Number of subjects: 16
Study 35129803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 35129995 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory context
Number of subjects: 45
Study 35129995 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) context
Number of subjects: 45
Study 35130025 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diabetes
Number of subjects: 1812
Study 35130025 — intervention group
Group type: COMPARATOR
Intervention: No maternal diabetes
Number of subjects: 1812
Study 35130025 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal diabetes or obesity
Number of subjects: 1812
Study 35130292 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for acute leukaemia during pregnancy; specific details on dosage and duration not available.
Number of subjects: 0
Study 35130292 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatment of acute leukaemia prior to pregnancy; specific details on treatment not available.
Number of subjects: 0
Study 35130339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 209
Study 35130417 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy maintenance
Number of subjects: 3867
Study 35130417 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy maintenance for hormone receptor-positive MBC patients
Number of subjects: 3867
Study 35130417 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy maintenance for hormone receptor-positive MBC patients
Number of subjects: 3867
Study 35130417 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy vs Endocrine therapy maintenance
Number of subjects: 3867
Study 35130491 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe global CRF (score of ≥40/100)
Number of subjects: 7902
Study 35130491 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe physical CRF
Number of subjects: 7902
Study 35130491 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe emotional CRF
Number of subjects: 7902
Study 35130505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NSCLC at diagnosis
Number of subjects: 76
Study 35130505 — intervention group
Group type: COMPARATOR
Intervention: Community controls, n=67
Number of subjects: 76
Study 35130505 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NSCLC
Number of subjects: 76
Study 35130557 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral stem cell delivery using a frame-based stereotactic delivery system
Number of subjects: 0
Study 35130557 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalizable protocol for intracerebral trajectory planning
Number of subjects: 0
Study 35130909 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma apolipoprotein concentrations
Number of subjects: 307
Study 35130909 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma apoE levels
Number of subjects: 307
Study 35130909 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoproteins (apoF, apoJ, apoL1)
Number of subjects: 307
Study 35130943 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 2 mg QD in Mild HD patients
Number of subjects: 46
Study 35130943 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1.5 mg QD in Moderate HD patients
Number of subjects: 46
Study 35130943 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib 1 mg QD in Severe HD patients
Number of subjects: 46
Study 35130943 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (various doses)
Number of subjects: 46
Study 35131031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary computed tomography (CT) and lung function (LF) assessments at 60, 100, and 180 days follow-up.
Number of subjects: 145
Study 35131031 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary computed tomography (CT) assessments.
Number of subjects: 145
Study 35131031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function (LF) assessments.
Number of subjects: 145
Study 35131031 — intervention group
Group type: EXPERIMENTAL
Intervention: Clustering and machine learning classifiers using non-CT and non-LF parameters.
Number of subjects: 145
Study 35131031 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of anti-S1/S2 antibody titer, IL-6, and CRP levels.
Number of subjects: 145
Study 35131040 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg orally once daily until treatment discontinuation, death, or study termination.
Number of subjects: 289
Study 35131040 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 289
Study 35131254 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ruxolitinib applied twice daily for 8 weeks
Number of subjects: 12
Study 35131513 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral challenge for penicillin allergy delabeling
Number of subjects: 0
Study 35131555 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oximetry-derived hypoxemia (ODI ≥30 events/hour)
Number of subjects: 1218
Study 35131555 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative screening using oximetry
Number of subjects: 1218
Study 35131660 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered behavioral strategies used by staff (41.9% modifications of resident abilities, 35.1% care approaches, 13.6% dining environment)
Number of subjects: 110
Study 35131660 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging behaviors exhibited by residents (35.7% resistive behaviors, 33.5% chewing/swallowing difficulties, 9.9% functional impairments, 20.9% positive/neutral behaviors)
Number of subjects: 110
Study 35131660 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between residents' challenging behaviors and staff person-centered behavioral strategies
Number of subjects: 110
Study 35131660 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic nonverbal behaviors
Number of subjects: 110
Study 35131826 — intervention group
Group type: EXPERIMENTAL
Intervention: WHO Safe Childbirth Checklist implementation
Number of subjects: 1559
Study 35131826 — intervention group
Group type: COMPARATOR
Intervention: Coaching-based implementation of the WHO Checklist
Number of subjects: 1559
Study 35131835 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced HIV disease (AHD) care package implementation
Number of subjects: 0
Study 35131835 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 test, tuberculosis-lipoarabinomannan assay, cryptococcal antigen lateral flow assay
Number of subjects: 0
Study 35131875 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA062 at 3.6 mg/kg every 2 weeks
Number of subjects: 47
Study 35131875 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA062 at various dose levels (0.4 to 5.0 mg/kg every 2 weeks)
Number of subjects: 47
Study 35131875 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA062
Number of subjects: 47
Study 35131903 — intervention group
Group type: COMPARATOR
Intervention: Olaparib maintenance monotherapy (300 mg orally twice daily until disease progression or unacceptable toxicity)
Number of subjects: 225
Study 35131903 — intervention group
Group type: COMPARATOR
Intervention: Olaparib maintenance monotherapy
Number of subjects: 225
Study 35132264 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES) targeting the dorsal roots of lumbosacral segments
Number of subjects: 3
Study 35132264 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-specific stimulation programs
Number of subjects: 3
Study 35132679 — intervention group
Group type: EXPERIMENTAL
Intervention: RsqVd (lenalidomide, subcutaneous bortezomib, and dexamethasone)
Number of subjects: 88
Study 35132704 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel (LAN) 120 mg/28 days for 1 year
Number of subjects: 50
Study 35132840 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning chronotype
Number of subjects: 48
Study 35132840 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study 35133093 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based CADe/x
Number of subjects: 32714
Study 35133093 — intervention group
Group type: COMPARATOR
Intervention: Standard mammography readings without AI-based CADe/x
Number of subjects: 32714
Study 35133112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 0
Study 35133112 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 0
Study 35133199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium MRI measuring CMG dynamics after water load in healthy volunteers
Number of subjects: 15
Study 35133199 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium MRI measuring CMG in participants with chronic kidney disease (CKD)
Number of subjects: 15
Study 35133199 — intervention group
Group type: COMPARATOR
Intervention: Urinary osmolarity
Number of subjects: 15
Study 35133221 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, dexamethasone, and daratumumab
Number of subjects: 0
Study 35133471 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient sleep (5 h/night)
Number of subjects: 12
Study 35133471 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery sleep
Number of subjects: 12
Study 35133604 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ-28 items)
Number of subjects: 766
Study 35133604 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 41 to 59 years
Number of subjects: 766
Study 35133604 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 766
Study 35133604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients affected by cancer
Number of subjects: 766
Study 35133604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without previous psychiatric treatment
Number of subjects: 766
Study 35133604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with relatives affected by cancer
Number of subjects: 766
Study 35133636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium/formoterol 400/12 µg twice daily
Number of subjects: 20
Study 35133636 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium
Number of subjects: 20
Study 35133636 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 20
Study 35133640 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring group (TMG)
Number of subjects: 256
Study 35133640 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 256
Study 35133982 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel chemotherapy
Number of subjects: 0
Study 35133982 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without CIPN
Number of subjects: 0
Study 35133982 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 35134165 — intervention group
Group type: EXPERIMENTAL
Intervention: T2Candida assay
Number of subjects: 500
Study 35134165 — intervention group
Group type: EXPERIMENTAL
Intervention: T2Candida and Platelia Candida Ag Plus assays (combined)
Number of subjects: 500
Study 35134259 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag 40 mg
Number of subjects: 39
Study 35134259 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatrombopag 60 mg
Number of subjects: 39
Study 35134259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 35134662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET) on a treadmill and exercise stress echocardiography on a lower limb cycle ergometer
Number of subjects: 31
Study 35134662 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPET)
Number of subjects: 31
Study 35134821 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro (FSL) devices
Number of subjects: 394
Study 35134821 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Number of subjects: 394
Study 35134821 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired CGMs
Number of subjects: 394
Study 35134880 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibezapolstat 450 mg orally every 12 hours for 10 days
Number of subjects: 10
Study 35134954 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert® Xpress Flu/RSV assay
Number of subjects: 561
Study 35134954 — intervention group
Group type: COMPARATOR
Intervention: RT-PCR
Number of subjects: 561
Study 35135065 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 651
Study 35135470 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 0
Study 35135499 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet-based intervention for diabetic hypoglycaemia (Hypos can strike twice)
Number of subjects: 159
Study 35135644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with CoronaVac
Number of subjects: 90
Study 35135700 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccination (two doses)
Number of subjects: 2
Study 35135810 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intratumoral immunotherapy with TLR9 ligand CpG and anti-OX40 antibody
Number of subjects: 0
Study 35135810 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intratumoral immunotherapy with TLR9 ligand CpG and anti-OX40 antibody plus systemic anti-PD1 antibody
Number of subjects: 0
Study 35135810 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant checkpoint blockade therapy (systemic)
Number of subjects: 0
Study 35135824 — intervention group
Group type: EXPERIMENTAL
Intervention: CCEDRRN COVID-19 Mortality Score
Number of subjects: 8761
Study 35135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated SARS-CoV-2 vaccine (CoronaVac)
Number of subjects: 260
Study 35135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 260
Study 35135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 260
Study 35135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of DMARD
Number of subjects: 260
Study 35135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (5-year interval)
Number of subjects: 260
Study 35135832 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone >7.5 mg/day
Number of subjects: 260
Study 35135832 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARD combinations
Number of subjects: 260
Study 35135966 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nonreactive EEG
Number of subjects: 52
Study 35135966 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuous EEG background
Number of subjects: 52
Study 35136124 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptom assessment of smell and taste loss
Number of subjects: 498
Study 35136124 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ratings of chemosensory function
Number of subjects: 498
Study 35136124 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of predictors
Number of subjects: 498
Study 35136124 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived nasal obstruction
Number of subjects: 498
Study 35136603 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic CD20-targeted γδ T cells
Number of subjects: 0
Study 35136603 — intervention group
Group type: COMPARATOR
Intervention: Autologous chimeric antigen receptor (CAR) αβ T-cell therapies
Number of subjects: 0
Study 35136878 — intervention group
Group type: EXPERIMENTAL
Intervention: Connected Ovulation Test System
Number of subjects: 0
Study 35136878 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35137142 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEAS level
Number of subjects: 287
Study 35137142 — intervention group
Group type: EXPERIMENTAL
Intervention: Midnight serum cortisol level
Number of subjects: 287
Study 35137142 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressed adrenocorticotropic hormone (≤2.2 pmol/L)
Number of subjects: 287
Study 35137142 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour urinary free cortisol
Number of subjects: 287
Study 35137154 — intervention group
Group type: EXPERIMENTAL
Intervention: GII.2 norovirus inoculum (1.2 × 10^4 to 1.2 × 10^7 genome equivalent copies [GEC]; n = 38)
Number of subjects: 44
Study 35137154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 44
Study 35137228 — intervention group
Group type: EXPERIMENTAL
Intervention: ONC201 treatment
Number of subjects: 24
Study 35137301 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge mortality within 30 days after discharge
Number of subjects: 7882
Study 35137301 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for post-discharge mortality
Number of subjects: 7882
Study 35137301 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for prediction of post-discharge mortality
Number of subjects: 7882
Study 35137481 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 101
Study 35137481 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine (BUP)
Number of subjects: 101
Study 35137627 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sublingual fentanyl
Number of subjects: 95
Study 35137871 — intervention group
Group type: EXPERIMENTAL
Intervention: ELMOcpap system (CPAP via ELMO interface with oxygen and compressed air flow meters at 30 L/min each, PEEP valve, CPAP levels = 8-10 cmH2O)
Number of subjects: 10
Study 35137871 — intervention group
Group type: EXPERIMENTAL
Intervention: ELMOcpap system (CPAP at 10 cmH2O, total gas flow of 56-60 L/min)
Number of subjects: 10
Study 35138325 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D LVEF
Number of subjects: 136
Study 35138325 — intervention group
Group type: EXPERIMENTAL
Intervention: GLS
Number of subjects: 136
Study 35138325 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS
Number of subjects: 136